Madhi Shabir A, Adrian Peter, Kuwanda Locadiah, Jassat Wasilla, Jones Stephanie, Little Tessa, Soininen Anu, Cutland Clare, Klugman Keith P
University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa.
Vaccine. 2007 Mar 22;25(13):2451-7. doi: 10.1016/j.vaccine.2006.09.019. Epub 2006 Sep 20.
The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.
在感染HIV和未感染HIV的儿童中研究了9价结合肺炎球菌疫苗的长期免疫原性和疫苗效力（VE）。在未感染HIV的儿童中，经过6.16年随访后，针对疫苗血清型侵袭性肺炎球菌疾病的疫苗效力持续存在（77.8%；95%可信区间34.4 - 92.5，相比2.3年随访后的83%），而在感染HIV的儿童中，该效力从65%降至38.8%（95%可信区间-7.8至65.2）。在5.3岁时，与感染HIV的疫苗接种者相比，未感染HIV的疫苗接种者针对所分析的疫苗血清型，血清型特异性抗体浓度≥0.2μg/ml的比例相同（血清型4、6B、14、19F）或更高（血清型9V、18C、23F）。
